94 related articles for article (PubMed ID: 28547957)
1. Review of prognostic and predictive aspects of mutated TP53 in Wilms' tumor biology with morphological report and molecular analysis of 37-year-old man's nephroblastoma.
Wincewicz A; Kowalik A; Zięba S; Kopczyński J; Góźdź S; Sulkowski S
Pol J Pathol; 2016; 67(4):307-312. PubMed ID: 28547957
[TBL] [Abstract][Full Text] [Related]
2. Relation between expression pattern of wild-type p53 and multidrug resistance proteins in human nephroblastomas.
Hodorová I; Rybárová S; Vecanová J; Solár P; Plank L; Mihalik J
Acta Histochem; 2013 Apr; 115(3):273-8. PubMed ID: 22925562
[TBL] [Abstract][Full Text] [Related]
3. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ
Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318
[TBL] [Abstract][Full Text] [Related]
4. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of GLUT1 and its correlation with unfavorable histology and TP53 codon 72 polymorphism in Wilms tumors.
Rakheja D; Khokhar S; Mitui M; Cost NG
Pediatr Dev Pathol; 2012; 15(4):286-92. PubMed ID: 22483234
[TBL] [Abstract][Full Text] [Related]
6. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.
Maschietto M; Williams RD; Chagtai T; Popov SD; Sebire NJ; Vujanic G; Perlman E; Anderson JR; Grundy P; Dome JS; Pritchard-Jones K
PLoS One; 2014; 9(10):e109924. PubMed ID: 25313908
[TBL] [Abstract][Full Text] [Related]
8. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.
Goswami RS; Patel KP; Singh RR; Meric-Bernstam F; Kopetz ES; Subbiah V; Alvarez RH; Davies MA; Jabbar KJ; Roy-Chowdhuri S; Lazar AJ; Medeiros LJ; Broaddus RR; Luthra R; Routbort MJ
Clin Cancer Res; 2015 Jun; 21(11):2644-51. PubMed ID: 25695693
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma.
Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Oomen MH; Noordzij MA; Van den Heuvel MM; Nassef SM; Nijman RM; Van Steenbrugge GJ
Clin Cancer Res; 2000 Nov; 6(11):4265-71. PubMed ID: 11106242
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.
Lahoti C; Thorner P; Malkin D; Yeger H
Am J Pathol; 1996 May; 148(5):1577-89. PubMed ID: 8623926
[TBL] [Abstract][Full Text] [Related]
11. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
Pritchard-Jones K; Fleming S
Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.
Malkin D; Sexsmith E; Yeger H; Williams BR; Coppes MJ
Cancer Res; 1994 Apr; 54(8):2077-9. PubMed ID: 8174107
[TBL] [Abstract][Full Text] [Related]
13. Nephroblastic neoplasms.
Khoury JD
Clin Lab Med; 2005 Jun; 25(2):341-61, vi-vii. PubMed ID: 15848740
[TBL] [Abstract][Full Text] [Related]
14. Mutations of p53 in Wilms' tumors.
Takeuchi S; Bartram CR; Ludwig R; Royer-Pokora B; Schneider S; Imamura J; Koeffler HP
Mod Pathol; 1995 Jun; 8(5):483-7. PubMed ID: 7675765
[TBL] [Abstract][Full Text] [Related]
15. [Expression of p53 in nephroblastoma and neuroblastoma].
Bu X; Shen Z; Jin B
Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):220-2. PubMed ID: 10374542
[TBL] [Abstract][Full Text] [Related]
16. Radiology case of the month. Asymptomatic abdominal mass in a child. Wilms' tumor (Nephroblastoma).
Costelloe CM; Neitzschman H
J La State Med Soc; 2001 May; 153(5):229. PubMed ID: 11433928
[No Abstract] [Full Text] [Related]
17. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
[TBL] [Abstract][Full Text] [Related]
18. Genetics of Wilms' tumor.
Coppes MJ; Egeler RM
Semin Urol Oncol; 1999 Feb; 17(1):2-10. PubMed ID: 10073400
[TBL] [Abstract][Full Text] [Related]
19. [Nephroblastoma (Wilms' tumor): cytogenetic and molecular biology principles].
Strohmeyer T
Klin Padiatr; 1993; 205(3):135-9. PubMed ID: 8394474
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.
Tretiakova M; Turkyilmaz M; Grushko T; Kocherginsky M; Rubin C; Teh B; Yang XJ
J Clin Pathol; 2006 Dec; 59(12):1272-7. PubMed ID: 16556665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]